Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials-Reference-Cited by-同舟云学术

Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): A combined analysis of three phase 3 trials

Published:2012-05 Issue:2 Volume:76 Page:222-227
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Treat Joseph,Scagliotti Giorgio V.,Peng Guangbin,Monberg Matthew J.,Obasaju Coleman K.,Socinski Mark A.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Cancer Statistics, 2010;Jemal;CA Cancer J Clin,2010

2. Estimates of the cancer incidence and mortality in Europe in 2006;Ferlay;Ann Oncol,2007

3. Screening, diagnosis, and staging of lung cancer;Shepherd;Curr Opin Oncol,1993

4. Chemotherapy for advanced non-small-cell lung cancer;Walling;Respir Med,1994

5. Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study;Kortsik;Lung Cancer,2003

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting of human cancer stem cells predicts efficacy and toxicity of FDA-approved oncology drugs;Cancer Letters;2024-09

2. Clinical presentation and outcome of patients with enteric-type adenocarcinoma of the lung: A pooled analysis of published cases;Lung Cancer;2023-05

3. Drug Resistance in Lung Cancer;Interdisciplinary Cancer Research;2022

4. Systematic review and meta-analysis of the predictive power of MTHFR polymorphisms for pemetrexed drug efficacy and toxicity in non-small cell lung cancer patients;Journal of Chemotherapy;2021-12-08

5. Plasma Endoglin is Associated with Favorable Outcome for Pemetrexed-Based Therapy in Advanced Non-Small Cell Lung Cancer;Cancer Management and Research;2021-12